share_log
  • 要闻
  • Spectral AI 宣布遵守纳斯达克上市规则，市场价值持续增长。

Spectral AI Announces Compliance With Nasdaq Listing Rule Amid Continued Growth in Market Value

Spectral AI Announces Compliance With Nasdaq Listing Rule Amid Continued Growth in Market Value

Spectral AI 宣布遵守纳斯达克上市规则，市场价值持续增长。
Quiver Quantitative ·  12/13 09:00

Spectral AI confirms compliance with Nasdaq market value requirements after exceeding $35 million in market capitalization for ten days.

Spectral AI确认在市值超过3500万后，符合纳斯达克市场价值要求，已持续十天。

Quiver AI Summary

Quiver AI 概要

Spectral AI, a Dallas-based company specializing in AI-driven medical diagnostics for wound care, announced that it has regained compliance with Nasdaq Listing Rule 5550(b)(2) by maintaining a market value of over $35 million for the past 10 consecutive trading days. This follows the company's development of the DeepView System, which utilizes multi-spectral imaging to assess burn healing potential, and received Breakthrough Device Designation from the FDA in 2018. The company is now awaiting confirmation from Nasdaq regarding its compliance status. Spectral AI aims to improve treatment decisions and patient outcomes in wound care through its innovative technology.

Spectral AI是一家总部位于达拉斯的公司，专注于人工智能驱动的伤口护理医疗诊断。该公司宣布，通过在过去的10个连续交易日内保持超过3500万的市场价值，已重新符合纳斯达克上市规则5550(b)(2)。这得益于公司开发的DeepView系统，该系统利用多光谱成像评估烧伤愈合潜力，并于2018年获得FDA的突破性设备认证。该公司现在在等待纳斯达克对其合规状态的确认。Spectral AI旨在通过其创新技术改善伤口护理中的治疗决策和患者结果。

Potential Positives

潜在的积极因素

  • Spectral AI has regained compliance with Nasdaq Listing Rule 5550(b)(2), which strengthens its position in the stock market and assures investors of its market value stability.
  • The company's market value has exceeded $35 million for the last 10 consecutive business days, indicating improved investor confidence and market perception.
  • The DeepView System, which uses advanced AI for predicting burn healing potential, continues to support the company's innovative approach in the medical diagnostics field, potentially leading to enhanced patient care and market differentiation.
  • Spectral AI已重新符合纳斯达克上市规则5550(b)(2)，这加强了其在股票市场的地位，并确保投资者对其市场价值的稳定性。
  • 公司的市场价值在过去的10个连续工作日内已超过3500万，显示出投资者信心和市场认知的改善。
  • DeepView系统利用先进的人工智能预测烧伤愈合潜力，持续支持公司在医疗诊断领域的创新方法，有望提高患者护理和市场差异化。

Potential Negatives

潜在负面因素

  • The announcement of regaining compliance with Nasdaq Listing Rule 5550(b)(2) indicates that the company had previously been at risk of delisting, which could signal financial instability or struggles in maintaining investor confidence.
  • The emphasis on the company's need to regain compliance may raise questions about its overall financial health and market perception, especially given that such compliance issues can affect investor relations.
  • The forward-looking statements regarding the company's future plans and strategies come with significant disclaimers about the risks and uncertainties involved, suggesting that there may be challenges ahead that could impact performance and growth.
  • 遵守纳斯达克上市规则5550(b)(2)的公告表明，该公司之前曾面临退市风险，这可能表明财务不稳定或投资者信心维持方面的困难。
  • 公司需要重新获得合规性的强调可能会引发有关其整体财务健康和市场认知的问题，特别是考虑到这样的合规问题可能影响投资者关系。
  • 关于公司未来计划和策略的前瞻性声明附带了关于风险和不确定性的重大免责声明，表明可能面临的挑战可能会影响业绩和增长。

FAQ

常见问题

What is Spectral AI's recent compliance announcement?

Spectral AI最近的合规公告是什么？

Spectral AI has announced it has regained compliance with Nasdaq Listing Rule 5550(b)(2), with a market value exceeding $35 million.

Spectral AI宣布其已重新获得遵守纳斯达克上市规则5550(b)(2)，市值超过3500万。

What does the DeepView System do?

DeepView系统的功能是什么？

The DeepView System uses multi-spectral imaging to predict burn healing potential, aiding in medical diagnostics and treatment decisions.

DeepView系统利用多光谱成像来预测烧伤愈合潜力，帮助医疗诊断和治疗决策。

When did the DeepView System receive FDA designation?

DeepView系统何时获得FDA认证？

The DeepView System received Breakthrough Device Designation from the U.S. FDA in 2018.

DeepView系统于2018年获得美国FDA的突破性医疗器械认证。

What is the focus of Spectral AI?

Spectral AI的重点是什么？

Spectral AI focuses on predictive AI for medical diagnostics, particularly in wound care including burns and diabetic foot ulcers.

Spectral AI专注于用于医疗诊断的预测人工智能，特别是在伤口护理方面，包括烧伤和糖尿病足溃疡。

How can I learn more about DeepView?

我如何能了解更多关于DeepView的信息？

For more information about DeepView, visit the company's website at .

有关DeepView的更多信息，请访问该公司的网站。

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

免责声明：这是由GlobeNewswire分发的新闻稿的人工智能生成摘要。用于总结这份稿件的模型可能会出错。请在这里查看完整发布。


$MDAI Hedge Fund Activity

$MDAI对冲基金活动

We have seen 12 institutional investors add shares of $MDAI stock to their portfolio, and 10 decrease their positions in their most recent quarter.

我们看到12个机构投资者在最近一个季度中增加了$MDAI股票的持股，10个减少了他们的持仓。

Here are some of the largest recent moves:

以下是最近的一些重大变动：

  • MORGAN STANLEY added 110,727 shares (+3261.5%) to their portfolio in Q3 2024
  • AVANTAX PLANNING PARTNERS, INC. added 95,493 shares (+148.4%) to their portfolio in Q3 2024
  • VANGUARD GROUP INC added 43,872 shares (+71.3%) to their portfolio in Q3 2024
  • MURCHINSON LTD. removed 40,000 shares (-100.0%) from their portfolio in Q2 2024
  • UBS GROUP AG added 39,105 shares (+3910500.0%) to their portfolio in Q3 2024
  • GEODE CAPITAL MANAGEMENT, LLC added 29,527 shares (+43.9%) to their portfolio in Q3 2024
  • MYDA ADVISORS LLC removed 20,000 shares (-100.0%) from their portfolio in Q2 2024
  • 摩根士丹利在2024年第三季度增加了110,727股（+3261.5%）的持股。
  • AVANTAX PLANNING PARTNERS, INC.在2024年第三季度增加了95,493股（+148.4%）的持股。
  • 先锋集团在2024年第三季度增加了43,872股（+71.3%）的持股。
  • MURCHINSON LTD.在2024年第二季度减少了40,000股（-100.0%）的持股。
  • 瑞银在2024年第三季度增加了39,105股（+3910500.0%）的持股。
  • GEODE CAPITAL MANAGEMENT, LLC在2024年第三季度新增29,527股(+43.9%)
  • MYDA ADVISORS LLC在2024年第二季度减持20,000股(-100.0%)

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

要跟踪对冲基金的股票投资组合，请查看Quiver Quantitative的机构持有情况仪表。

Full Release

完整发布



DALLAS, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) ("Spectral AI" or the "Company"), developer of the AI-driven DeepView



System, which received Breakthrough Device Designation from the U.S. FDA in 2018, that uses multi-spectral imaging and algorithms to predict burn healing potential, today announced today that the Company believes it has regained compliance with Nasdaq Listing Rule 5550(b)(2), which requires listed companies to maintain a minimum market value of listed securities of $35 million.


达拉斯，2024年12月13日（环球新闻）-- 光谱人工智能（纳斯达克：MDAI）（"光谱人工智能"或"公司"），人工智能驱动的DeepView系统开发者，



该系统于2018年获得美国FDA的突破性医疗器械设计认证，利用多光谱成像和算法预测烧伤愈合潜力，今天公司宣布相信已重新符合纳斯达克上市规则5550(b)(2)的要求，该规则要求上市公司保持至少3500万美元的上市证券最低市场价值。



The market value of Spectral AI's common stock has exceeded $35 million at the close of trading for the last 10 consecutive business days, as required by Nasdaq rules. The company has notified Nasdaq of its compliance and is awaiting confirmation from the exchange.


根据纳斯达克的规则，光谱人工智能的普通股市场价值在过去10个连续的交易日结束时已超过3500万美元。公司已通知纳斯达克其合规性，并正在等待交易所的确认。




About Spectral AI



本新闻稿中的某些声明是“前瞻性声明”，在美国《私人证券诉讼改革法》第21E条的“安全港”规定下进行。这些前瞻性声明涉及到公司的策略、计划、目标、倡议和财务展望。在本新闻稿中使用的“估计”、“预计”、“预测”、“计划”、“打算”、“相信”、“寻求”、“可能”、“将”、“应该”、“未来”、“建议”及其变体或类似表达（或这些单词或表达的否定版本）旨在识别前瞻性声明。



Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by "Seeing the Unknown



" with its DeepView



System. DeepView is a predictive device that offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, DeepView is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView, visit



.


Spectral AI, Inc.是一家位于达拉斯的预测人工智能公司，专注于医疗诊断，以便更快速和准确地为伤口护理作出治疗决策，最初的应用涉及烧伤和糖尿病足溃疡患者。该公司正在努力通过“看见未知”来革新伤口护理的管理。



与其DeepView系统。



DeepView是一个预测设备，能够在治疗或其他医疗干预之前，客观、即时地评估伤口的愈合潜力。通过算法驱动的结果及在未来超越当前护理标准的目标，DeepView预计将提供更快速、更准确的治疗洞察，从而改善患者的治疗效果，降低医疗成本。有关DeepView的更多信息，访问



.




Forward-Looking Statements



前瞻性声明



Certain statements made in this release are "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company's intention to separate its Spectral IP subsidiary from the Company, and each Company's strategy, plans, objectives, initiatives, strategic goals, financial outlook or other non-historical matters. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.


Certain statements made in this release are "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company's intention to separate its Spectral IP subsidiary from the Company, and each Company's strategy, plans, objectives, initiatives, strategic goals, financial outlook or other non-historical matters. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.



These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.


These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.



Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" sections of the Company's filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Spectral AI undertakes no obligation to update any forward-looking statements except as otherwise required by law.


投资者应仔细考虑上述因素以及公司在向美国证券交易委员会提交的文件中描述的其他风险和不确定性，包括注册声明和公司提交的其他文件。这些文件识别并处理其他重要风险和不确定性，这些风险和不确定性可能导致实际事件和结果实质性偏离前瞻性声明中包含的内容。除法律要求外，Spectral AI不承担更新任何前瞻性声明的义务。



For Media and Investor Relations, please contact:


如需媒体和投资者关系信息，请联系：



David Kugelman
Atlanta Capital Partners LLC
(866) 692-6847 Toll Free - U.S. & Canada
(404) 281-8556 Mobile and WhatsApp
Email:

dk@atlcp.com


大卫·库格尔曼
亚特兰大资本合作伙伴有限公司
(866) 692-6847 免费电话 - 美国及加拿大
(404) 281-8556 手机和WhatsApp
电子邮件：

dk@atlcp.com



声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间